Plain-English translation of NCT06992804 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether combining near-infrared light therapy (a special type of light treatment applied to the head) with lecanemab, a new Alzheimer's medication, works better than the medication alone for people with mild Alzheimer's disease. Lecanemab is designed to target amyloid protein buildup in the brain, which is believed to contribute to Alzheimer's disease. The study will check whether adding the light therapy improves how well the medication works and is safe to use.
Alzheimer's disease is a progressive brain condition that affects memory and thinking. Researchers are exploring whether combining this medication with a light-based treatment might offer better protection against memory loss than the medication by itself.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the real light therapy device combined with the medication, or a sham (fake) device combined with the medication for the first 16 weeks. After that initial phase, you'll have the option to continue for another 32 weeks receiving the real light therapy with the medication. Throughout the study, you'll visit the hospital for assessments, brain imaging tests, and memory evaluations, and you'll use the device regularly at home with your caregiver's help.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
China